Stock Catalyst AI
?? VIP Login VIP €10

Ticker archive · $LLY

$LLY Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $LLY — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$LLY

$LLY – Eli Lilly Q3 Results Beat Estimates; Raises FY Revenue Guidance

· TELEGRAM · All $LLY
?? Positive AI Sentiment (+6.8 / 10)
  • Q3 revenue of $24.40B beats consensus of $22.52B, driven by Mounjaro sales of $10.7B.
  • Adj. EPS of $7.48 tops expectations of $5.59.
  • FY revenue guidance lifted to $91.0B-$92.0B (prev. $85.0B-$87.0B); FY adj. EPS trimmed slightly to $35.00-$36.00.
Observed market reaction after signal
4h +6.67% · Peak +9.32%
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?
$LLY

$LLY – Eli Lilly Beats Q3 Estimates Across Top and Bottom Line, Raises FY Revenue Outlook

· TELEGRAM · All $LLY
?? Positive AI Sentiment (+6.8 / 10)
  • Q3 Revenue of $24.40B beats $22.52B estimate; Adj. EPS of $7.48 tops $5.59 consensus.
  • Blockbusters Mounjaro ($10.7B vs $9.95B) and Zepbound ($5.35B vs $5.01B) exceed expectations.
  • FY revenue guidance raised to $91.0B–$92.0B; FY Adj. EPS slightly lowered to $35.00–$36.00.
Observed market reaction after signal
4h +6.67% · Peak +9.32%
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?
$LLY

$LLY – Eli Lilly Q3 Adj. EPS $7.48 vs $5.59 est., Raises FY Revenue Guidance

· TELEGRAM · All $LLY
?? Positive AI Sentiment (+6.8 / 10)
  • Q3 revenue reached $24.40B (est. $22.52B), Adj. EPS of $7.48 easily beat $5.59 consensus.
  • Blockbuster drugs Mounjaro ($10.7B) and Zepbound ($5.35B) beat market expectations.
  • FY revenue guidance raised to $91B-$92B (prior $85B-$87B); FY Adj. EPS guided to $35-$36 (prior $35.50-$36.50).
Observed market reaction after signal
4h +6.64% · Peak +9.32%
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?
$LLY

$LLY – Eli Lilly's Retatrutide Outperforms Ozempic in Weight Loss and Glucose Control Trial

· TELEGRAM · All $LLY
?? Positive AI Sentiment (+6.5 / 10)
  • Eli Lilly reported clinical trial data where Retatrutide outperformed Novo Nordisk's Ozempic.
  • Superior outcomes demonstrated in both weight loss and blood sugar control.
  • Enhances Lilly's long-term competitive pipeline in the obesity market.
Observed market reaction after signal
4h -0.25% · Peak +0.67%
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?